Effect of tranilast on facial neuralgia

JRCT ID: jRCTs061230013

Registered date:12/05/2023

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Trigeminal neuralgia
• Date of first enrollment: 25/10/2023
• Target sample size: 15
• Study type: Interventional
• Intervention(s): Tranilast is administered orally, taking one capsule (100 mg) three times a day.

Outcome(s)

• Primary Outcome: visual analogue scale
• Secondary Outcome: Precision tactile function inspection value

Key inclusion & exclusion criteria

• Age minimum: >= 50age old
• Age maximum: <= 80age old
• Gender: Both

Include criteria

Patients who visit Tokushima University Hospital's Department of Fixed Prosthodontics, Temporomandibular Disorder Clinic, Department of Dental Anesthesiology
Patients diagnosed with trigeminal neuralgia according to the International Classification of Orofacial Pain
Patients aged 50 to 80

• Exclude criteria: Patients with secondary trigeminal neuralgia who find organic changes in the brain by CT or MRI, patients taking warfarin, patients planning to move, pregnant women (especially within about 3 months) or possibly pregnant, patients deemed inappropriate by the principal investigator

Related Information

• Primary Sponsor: Ikutame Daisuke